NJ-based Cosette Pharmaceutical Acquired Vyleesi® from Palatin Technologies, Inc. (NYSE: PTN), which includes 5 Orange Book listed patents with protection up to 2041. Palatin and Cosette will ensure continued patient and healthcare professional access to VyleesiⓇ throughout the transition period.
Read also – CA-based Hyperlink Ventures Secures it’s First fund at $32M
Apurva Saraf, President and CEO of Cosette said, “This acquisition highlights Cosette’s continued focus on improving women’s health, and our dedication to increasing awareness and education, Our strong commercial capabilities, coupled with our commitment to partnering with the women’s health community will drive improved access to VyleesiⓇ for the millions of women who suffer from HSDD.”
HSDD is the most common female sexual dysfunction condition in the U.S., impacting approximately 6 million premenopausal women. HSDD is defined as a persistent or recurrent absence of sexual fantasies and desire for sexual activity, which causes marked personal distress or interpersonal difficulties.
Read also – ME-based Biochar Producer Standard Biocarbon Secures $5M in Funding
Rachel Rubin, M.D., Urologist and Sexual Medicine Specialist Vyleesi® said, “HSDD has been a recognized medical condition for over 40 years, but is widely underdiagnosed and undertreated, is a welcome tool in our biopsychosocial toolbox. It is a novel and effective treatment option for HSDD that can be self-administered as needed in anticipation of sexual activity. Women with HSDD should not ignore or justify their symptoms and should talk to their healthcare provider about reclaiming their sexual desire.”
Cosette is committed to working with healthcare professionals to help ensure women with HSDD have access to VyleesiⓇ. Cosette offers patients the ability to connect with a physician through a telemedicine option.
Read also – CA-based Vasa Therapeutics Secures a Seed Funding
About Cosette Pharmaceuticals
Cosette Pharmaceuticals, Inc. (“Cosette”) is a US-based, fully integrated pharmaceutical company with a fast- growing portfolio of branded pharmaceuticals consisting of products in women’s health, cardiology and dermatology.
Read also – Wakarusa-based iFlock Security Consulting Secures an Undisclosed Amount of Funding
